# An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

> **NCT06749886** · PHASE2 · RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 22 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Denosumab
- **DRUG:** tislelizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06749886
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-19
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06749886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06749886, "An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06749886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*